MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
QURE stock logo

QURE

uniQure N.V.

$17.16
0.27
 (1.6%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  1.057B
Shares Outstanding:  17.595M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Matthew Craig Kapusta
Full Time Employees:  209
Address: 
Paasheuvelweg 25a
Amsterdam
1105 BP
NL
Website:  https://www.uniqure.com
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/09 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue15,84327,11916,098
Gross Profit2,2158,792-347
EBITDA-253,100-160,745-178,581
Operating Income-282,871-184,294-185,470
Net Income-308,478-239,556-198,971

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets831,689556,536824,908
Total Liabilities624,019563,288626,007
Total Stockholders Equity207,670-6,752198,901
Total Debt138,40966,06163,393
Cash and Cash Equivalents241,360158,93080,240

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-145,929-182,728-177,963
Capital Expenditure-7,154-3,3680
Free Cash Flow-153,083-186,096-177,963
Net Income-308,478-239,556-198,971
Net Change in Cash13,371-84,2150

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)243,166.956Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,277,876.622Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)581,750.143Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-866,713.096Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-164,926.708Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-394,568.974Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)21,293.016Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)223,576.669Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)87,485.372Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)498,587.023Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)2,620,145.071Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,192,814.504Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.520Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)3.890Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.370Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)7Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)5Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
15.843M  ?P/S
 (TTM)
: 
67.28
?Net Income
 (TTM)
: 
-308478000  ?P/E
 (TTM)
: 
-5.08
?Enterprise Value
 (TTM)
: 
1.539B  ?EV/FCF
 (TTM)
: 
-8.65
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-1.74  ?ROIC
 (TTM)
: 
-0.24
?Net Debt
 (TTM)
: 
59.042M  ?Debt/Equity
 (TTM)
: 
2.7
?P/B
 (TTM)
: 
5.08  ?Current Ratio
 (TTM)
: 
10.43

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate QURE Intrinsic Value

Common questions about QURE valuation

Is QURE (QURE) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for QURE (QURE) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is QURE a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether QURE trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is QURE’s P/E ratio?

You can see QURE’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for QURE?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is QURE a good long-term investment?

Whether QURE fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

QURE

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

1.6
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
QURE CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
uniQure N.V. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V.
QURE Deadline: Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
QURE FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read